PAVmed Inc.

NasdaqCM:PAVM Stock Report

Market Cap: US$9.3m

PAVmed Future Growth

Future criteria checks 0/6

PAVmed's revenue and earnings are forecast to decline at 47.8% and 173.9% per annum respectively while EPS is expected to decline by 172.8% per annum.

Key information

-173.9%

Earnings growth rate

-172.76%

EPS growth rate

Medical Equipment earnings growth12.7%
Revenue growth rate-47.8%
Future return on equityn/a
Analyst coverage

Low

Last updated04 Oct 2025

Recent future growth updates

Recent updates

User avatar

Veris Health's NIH Grant May Boost Future Revenue, But Financing Uncertainty Could Persist

Strategic restructuring and subsidiary deconsolidation aim to strengthen the financial structure and improve net margins.

Are Investors Undervaluing PAVmed Inc. (NASDAQ:PAVM) By 28%?

Jan 29
Are Investors Undervaluing PAVmed Inc. (NASDAQ:PAVM) By 28%?

Is PAVmed (NASDAQ:PAVM) Using Debt In A Risky Way?

Aug 17
Is PAVmed (NASDAQ:PAVM) Using Debt In A Risky Way?

PAVmed Non-GAAP EPS of -$0.17 beats by $0.03

Aug 16

PAVmed Continues To Have Lots Of Potential But EsoGuard Determines Short-Term Progress

Jul 05

Start Accumulating PAVmed

Dec 24

We Think PAVmed (NASDAQ:PAVM) Can Afford To Drive Business Growth

Sep 02
We Think PAVmed (NASDAQ:PAVM) Can Afford To Drive Business Growth

PAVmed: Long Term Investment Case Remains Despite Weak Q2

Aug 23

PAVmed (NASDAQ:PAVM) Is In A Good Position To Deliver On Growth Plans

May 19
PAVmed (NASDAQ:PAVM) Is In A Good Position To Deliver On Growth Plans

Do Institutions Own PAVmed Inc. (NASDAQ:PAVM) Shares?

Dec 16
Do Institutions Own PAVmed Inc. (NASDAQ:PAVM) Shares?

Earnings and Revenue Growth Forecasts

NasdaqCM:PAVM - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20260-15N/A-191
12/31/20250-2N/A-121
6/30/2025170-11-12N/A
3/31/2025272-22-22N/A
12/31/2024332-33-34N/A
9/30/2024415-46-46N/A
6/30/20244-67-48-48N/A
3/31/20243-71-49-49N/A
12/31/20232-66-52-52N/A
9/30/20232-71-56-57N/A
6/30/20231-79-69-65N/A
3/31/20231-90-79-75N/A
12/31/20220-89-76-71N/A
9/30/20221-86-79-71N/A
6/30/20221-72-64-60N/A
3/31/20221-58-48-44N/A
12/31/20211-51-44-41N/A
9/30/20210-42-31-31N/A
6/30/2021N/A-35-29-28N/A
3/31/2021N/A-30-27-27N/A
12/31/2020N/A-35-22-22N/A
9/30/2020N/A-32-19-19N/A
6/30/2020N/A-30-16-16N/A
3/31/2020N/A-28-13-13N/A
12/31/2019N/A-17-13-13N/A
9/30/2019N/A-17-12-12N/A
6/30/2019N/A-17-11-11N/A
3/31/2019N/A-19N/A-10N/A
12/31/2018N/A-19N/A-9N/A
9/30/2018N/A-12N/A-7N/A
6/30/2018N/A-14N/A-8N/A
3/31/2018N/A-10N/A-7N/A
12/31/2017N/A-10N/A-7N/A
9/30/2017N/A-12N/A-6N/A
6/30/2017N/A-9N/A-5N/A
3/31/2017N/A-9N/A-6N/A
12/31/2016N/A-6N/A-4N/A
9/30/2016N/A-5N/A-4N/A
6/30/2016N/A-3N/A-3N/A
3/31/2016N/A-2N/A-2N/A
12/31/2015N/A-2N/A-1N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: PAVM's earnings are forecast to decline over the next 3 years (-173.9% per year).

Earnings vs Market: PAVM's earnings are forecast to decline over the next 3 years (-173.9% per year).

High Growth Earnings: PAVM's earnings are forecast to decline over the next 3 years.

Revenue vs Market: PAVM's revenue is expected to decline over the next 3 years (-47.8% per year).

High Growth Revenue: PAVM's revenue is forecast to decline over the next 3 years (-47.8% per year).

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if PAVM's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/10/06 16:09
End of Day Share Price 2025/10/03 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

PAVmed Inc. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Edward WooAscendiant Capital Markets LLC
Raymond MyersBenchmark Company
Anthony VendettiMaxim Group